Table 5.
Demographic and clinical characteristics of 65 acute myeloid leukemia (AML) patients
| Characteristics | Patients |
|---|---|
|
Gender patients (male/female) |
65 (37/28) |
|
Age, median (range) |
51 (16-76) |
|
WBC count (X109/L), median (range) |
13.4 (0.580-292) |
|
Hemoglobin (g/dL), median (range) |
9.6 (5.6-12.7) |
|
Platelet count (X109/L), median (range) |
68 (11-538) |
|
ECOG PS, 0/1/2/3/4 |
17/18/20/9/1 |
|
FAB |
2/5/11/9/6/12/0/2/2/11 |
| 10/M1/M2/M3/M4/M5/M6/M7/bilineal/AML-NK/Unclassifiable) | |
|
WHO |
14/16/3/31 |
| current genetic abnormalities/multilineage dysplasia/therapy-related/not otherwise categorized) | |
|
De novo AML/Secondary AML |
51/14 |
|
Cytogenetic risk group, (MRC) unfavorable/intermediate/unfavorable/no cytogenetic information) |
15/31/12/7 |
|
Blasts in peripheral blood (%), median (range) |
32.5 (2-98) |
|
Blasts in bone marrow (%), median (range) |
79 (20-100) |
|
Alterations in Chromosome 5/Chromosome 7/Chromosome11/without results |
7 (11.9%)/7 (11.9%)/11 (22.9%)/6 |
|
Blast CD34+ (YES/NO) |
33/31 |
|
Blast CD117 (YES/NO) |
41/23 |
|
Blast CD56+YES/NO) |
11/54 |
|
Blast CD133+(YES/NO) |
20/27 |
|
Blast CD123+(YES/NO) |
12/23 |
|
Blast HLA-DR+(YES/NO) |
34/21 |
| Patient eligible/not eligible for treatment | 50/15 |